Equities

Iterum Therapeutics PLC

ITRM:NAQ

Iterum Therapeutics PLC

Actions
  • Price (USD)1.09
  • Today's Change0.000 / 0.00%
  • Shares traded109.65k
  • 1 Year change+43.61%
  • Beta2.2560
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments246181
Total Receivables, Net0.040.400.37
Total Inventory------
Prepaid expenses1.431.090.68
Other current assets, total0.200.120.84
Total current assets266283
Property, plant & equipment, net0.601.843.83
Goodwill, net------
Intangibles, net01.723.44
Long term investments------
Note receivable - long term------
Other long term assets0.030.800.91
Total assets266792
LIABILITIES
Accounts payable5.002.770.88
Accrued expenses8.134.681.63
Notes payable/short-term debt000
Current portion long-term debt/capital leases--01.63
Other current liabilities, total0.401.618.81
Total current liabilities149.0613
Total long term debt192825
Total debt192827
Deferred income tax------
Minority interest------
Other liabilities, total0.191.303.44
Total liabilities333941
SHAREHOLDERS EQUITY
Common stock0.140.131.83
Additional paid-in capital455451427
Retained earnings (accumulated deficit)(461)(423)(378)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.00(0.35)--
Total equity(6.4)2850
Total liabilities & shareholders' equity266792
Total common shares outstanding131312
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.